ACTUATE THERAPEUTICS, INC.
ACTU$42M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaFORT WORTH10 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
ACTU News
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
9-ING-41 Phase 2 Est. Readout
June 2026~Estimated9-ING-41350
Primary completion for 9-ING-41 trial (NCT03678883) in Cancer
SourceDrug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ruxolitinib | Phase 2 | Myelofibrosis | - | Patent 2041 |
9-ING-41 | Phase 2 | Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply